Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
domenica, ottobre 18
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Altimmune Inc
ALT
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$2.20
-0.16
-6.78%
Ult. Agg.: Oct 16, 7:57 PM
$2.22
-0.14
-5.94%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
Altimmune Financials
Altimmune (ALT) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Altimmune Q2 EPS $(0.12) Beats $(0.15) Estimate
Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 20 percent. This is a 55.56 percent increase over losses of $(0.27) per share from the same
Benzinga Newsdesk
PRO
Altimmune Q1 EPS $(0.18) Beats $(0.25) Estimate.
Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.25) by 28 percent. This is a 30.77 percent increase over losses of $(0.26) per share from the same
Benzinga Newsdesk
Earnings Scheduled For May 13, 2026
Benzinga Insights
Altimmune: Q4 Earnings Insights
Benzinga Insights
PRO
Altimmune Q4 EPS $(0.27) Up From $(0.33) YoY, Sales $26.000K Up From $5.000K YoY
Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.27) per share. This is a 18.18 percent increase over losses of $(0.33) per share from the same period last year. The company reported $26.000 thousand in sales
Benzinga Newsdesk
Earnings Scheduled For March 5, 2026
Benzinga Insights
